Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine
Open Access
- 1 May 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (9) , 1271-1281
- https://doi.org/10.1086/429240
Abstract
Background. Two previous trials have suggested that a herpes simplex virus (HSV) type 2 glycoprotein D (gD) vaccine combined with the adjuvants alumKeywords
This publication has 9 references indexed in Scilit:
- Recent Herpes Simplex Virus Type 2 Infection and the Risk of Human Immunodeficiency Virus Type 1 Acquisition in IndiaThe Journal of Infectious Diseases, 2003
- How Does Herpes Simplex Virus Type 2 Influence Human Immunodeficiency Virus Infection and Pathogenesis?The Journal of Infectious Diseases, 2003
- Analysis of Adverse Events after Anthrax Immunization in US Army Medical PersonnelJournal of Occupational and Environmental Medicine, 2003
- Glycoprotein-D–Adjuvant Vaccine to Prevent Genital HerpesNew England Journal of Medicine, 2002
- Risk of Human Immunodeficiency Virus Infection in Herpes Simplex Virus Type 2–Seropositive Persons: A Meta‐analysisThe Journal of Infectious Diseases, 2002
- The Effect of Injection Speed on the Perception of Intramuscular Injection PainAAOHN Journal, 2001
- Herpes Simplex Virus Type 2 in the United States, 1976 to 1994New England Journal of Medicine, 1997
- Side Effects Associated With Influenza Vaccination in Healthy Working AdultsArchives of internal medicine (1960), 1996
- Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpesThe Lancet, 1994